Success Story: Rapid EB-1A Approval for a Cancer Biology Researcher Advancing Precision Oncology
Client’s Testimonial:
"My experience with the Chen Immigration met all my expectations and more. The attorneys were methodical, allowing me to easily track all incremental changes being made in putting together my profile. The overall crafting of the profile was excellent and helped appropriately emphasize the impact of my work for the purposes of the petition. Importantly, the attorneys were receptive to suggested changes, ensuring no gaps were left in profile building. Overall, a very positive experience.”
On April 2nd, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Scientist in the Field of Cancer Biology (Approval Notice).
General Field: Cancer Biology
Position at the Time of Case Filing: Research Scientist
Country of Origin: India
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: April 2nd, 2026
Processing Time: 17 days (Premium Processing Requested)
Case Summary:
When a research scientist from India pursued permanent residency based on his work in cancer biology, North America Immigration Law Group (Chen Immigration Law Associates) built the case around a research theme with direct clinical stakes: why some cancers resist treatment, and how those resistance mechanisms can be exposed and targeted more effectively. His petition was approved on April 2nd, 2026, after just 17 days with Premium Processing.
The record showed the client working at the intersection of targeted cancer therapy, genomic stability, and functional genomics. The petition emphasized his investigations into therapeutic resistance in mutated cancers, the molecular drivers of chemotherapy response, and the underlying mechanisms of genome stability. These were presented not as isolated discoveries, but as part of a larger effort to improve precision cancer treatment by identifying why tumors survive therapy and which vulnerabilities can still be exploited.
One recommendation letter captured the importance of that work directly: “[Client]’s work on the impact of DNA replication fork stability on genome stability is of doubtless importance in enhancing our understanding of cancer etiology and therapeutic outcomes.”
We highlighted how unusually strong his objective record was. The petition documented:
- 11 peer-reviewed journal articles, including 4 first-authored or co-first-authored
- 730 citations
- Evidence placing him in the top 1% most highly cited authors publishing on molecular biology topics over the past 7 years
- At least 11 completed peer reviews
- Ongoing service as a topic editor
- Supported by NIH funding
Researchers at institutions in the United States and abroad actively used his work to study targeted therapeutic sensitivity, DNA repair mechanisms, advanced genetic screening, and signaling pathways linked to cancer progression and resistance. That pattern of independent reliance helped demonstrate that his findings were actively shaping the field.
This fast approval reflects the strength of a carefully prepared petition built on original contributions, broad scholarly influence, and clear clinical relevance. We were proud to help secure this result for a researcher whose work is advancing the understanding of treatment resistance and helping lay the groundwork for more effective cancer therapies in the United States.